Targeted agents in GI radiotherapy: Clinical efficacy and side effects

Area of Science:

• Oncology
• Radiation Oncology
• Gastrointestinal Malignancies

Background:

• Radiotherapy (RT) is a cornerstone cancer treatment, but dose escalation is limited by toxicity to surrounding tissues.
• Chemoradiotherapy (CRT) improves outcomes in gastrointestinal cancers but increases toxicity due to non-specific chemotherapy agents.
• Targeted agents offer pathway-specific modulation to enhance RT efficacy but have shown disappointing results in gastrointestinal malignancies.

Purpose of the Study:

• To review targeted therapies used in combination with RT/CRT for gastrointestinal malignancies.
• To examine the efficacy and toxicity of these combined treatment approaches.
• To outline challenges and future perspectives for optimizing targeted agent use with RT/CRT.

Main Methods:

• Literature review of clinical studies on targeted agents combined with RT/CRT in gastrointestinal cancers.
• Analysis of efficacy, toxicity, and biomarker data.
• Discussion of current limitations and future research directions.

Main Results:

• Most clinical studies combining targeted agents with RT/CRT in gastrointestinal malignancies have yielded disappointing results.
• Significant challenges exist, including lack of validated biomarkers for predicting treatment response and monitoring efficacy.
• Toxicity remains a concern, necessitating careful patient selection and treatment planning.

Conclusions:

• The combination of targeted agents with RT/CRT in gastrointestinal malignancies requires further optimization.
• Development of predictive biomarkers and refined treatment strategies are crucial for future clinical success.
• Addressing toxicity and improving efficacy remain key challenges for advancing targeted therapy in this setting.